CSL Pays $355M Upfront for Alentis Kidney/Liver Drug in $1.6B Deal
CSLLY sits 91% above its 52-week low of $16.01 on light trading volume (0.3× avg).
Summary
CSL is paying $355M upfront to partner with Alentis on lixudebart, an experimental antibody for kidney and liver diseases, with up to $1.2B more in commercial milestones. The deal gives CSL 55% of global profits and expands its nephrology pipeline, but it also takes on the cost of ongoing and planned trials. Interim Phase 2 data in 26 patients showed improved kidney function, though the drug hasn't proven efficacy in a pivotal trial yet. This is a meaningful bet on a rare disease asset with early but unconfirmed signals.
At the time of this announcement, CSLLY was trading at $30.54 on OTC in the Life Sciences sector, with a market capitalization of approximately $58.3B. The 52-week trading range was $16.01 to $36.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.